Day: January 8, 2021

NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) — Tastemaker Acquisition Corp. (the “Company”), a newly organized blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, today announced the pricing of its upsized initial public offering of 24,000,000 units at an initial public offering price of $10.00 per unit. The units will be listed on The Nasdaq Capital Market (“Nasdaq”) and trade under the ticker symbol “TMKRU” beginning on January 8, 2021. Each unit consists of one share of our Class A common stock and one-half of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one share of our Class A common stock at a price of $11.50 per share....

Interim Financial Statements for 12 months of 2020                     15 February 2021Audited annual report for 2020                                                     19 March 2021Interim Financial Statements for 3 months of 2021                       6 May 2021Annual General Meeting of Unitholders                                         2 June 2021Interim Financial Statements for 6 months of 2021                       5 August 2021Interim Financial Statements for 9 months of 2021                       4 November 2021Interim Financial Statements for 12 months of 2021                     15 February 2022Additional information:  Tarmo KarotamBaltic Horizon Fund managerE-mail tarmo.karotam@nh-cap.comwww.baltichorizon.com The Fund is a registered contractual public closed-end real estate fund that is managed by Alternative Investment Fund...

New York and Mainz, Germany, January 8, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an in vitro study conducted by Pfizer and the University of Texas Medical Branch (UTMB) that shows the antibodies from people who have received the Pfizer-BioNTech COVID-19 vaccine effectively neutralize SARS-CoV-2 with a key mutation that is also found in two highly transmissible strains. The results were published on the preprint server bioRxiv and are available here.Rapidly spreading variants of SARS-CoV-2 have been reported, initially in the United Kingdom and South Africa. These variants have multiple mutations in their spike or S glycoproteins, which are key targets of virus neutralizing antibodies. Though these two rapidly spreading viruses are different, they share the N501Y mutation, which is located...

New York und Mainz, Deutschland 08. Januar 2021 — Pfizer Inc. (NYSE: PFE) und BioNTech SE (Nasdaq: BNTX) gaben heute Ergebnisse einer in vitro-Studie bekannt, die zeigen, dass Personen, die den Pfizer-BioNTech-COVID-19-Impfstoff erhalten haben, Antikörper gebildet haben, die SARS-CoV-2 mit einer Schlüsselmutation effizient neutralisieren. Diese Mutation wurde auch in zwei hochinfektiösen Virusvarianten nachgewiesen. Die Studie wurde von Pfizer und der University of Texas Medical Branch (UTMB) durchgeführt. Die Ergebnisse wurden auf dem Preprint-Server bioRxiv veröffentlicht und sind hier verfügbar.SARS-CoV-2-Varianten mit höherer Ansteckungsrate wurden zunächst im Vereinigten Königreich und in Südafrika nachgewiesen. Diese Varianten haben eine Reihe von Mutationen in ihrem Spike- oder S-Glykoprotein, die einer der Hauptangriffspunkte...

Interim Financial Statements for 12 months of 2020                     15 February 2021Audited annual report for 2020                                                     19 March 2021Interim Financial Statements for 3 months of 2021                       6 May 2021Annual General Meeting of Unitholders                                         2 June 2021Interim Financial Statements for 6 months of 2021                       5 August 2021Interim Financial Statements for 9 months of 2021                       4 November 2021Interim Financial Statements for 12 months of 2021                     15 February 2022Additional information:  Tarmo KarotamBaltic Horizon Fund managerE-mail tarmo.karotam@nh-cap.comwww.baltichorizon.com The Fund is a registered contractual public closed-end real estate fund that is managed by Alternative Investment Fund...

Q4 2020. aasta vahearuanne (auditeerimata konsolideeritud)         15. veebruar 2021Auditeeritud konsolideeritud 2020. majandusaasta aruanne            19. märts 2021Q1 2021. aasta vahearuanne (auditeerimata konsolideeritud)         6. mai 20212020. majandusaasta osakuomanike korraline üldkoosolek             2. juuni 2021Q2 2021. aasta vahearuanne (auditeerimata konsolideeritud)         5. august 2021Q3 2021. aasta vahearuanne (auditeerimata konsolideeritud)         4. november 2021Q4 2021. aasta vahearuanne (auditeerimata konsolideeritud)         15. veebruar 2022Lisainformatsiooni saamiseks palume ühendust võtta:

CONTRAT DE LIQUIDITE ET OU PROGRAMME DE RACHATTABLEAU DE DECLARATION MENSUELLE DES OPERATIONS REALISEESPAR UN EMETTEUR SUR SES PROPRES TITRESINFORMATIONS CUMULEES Nombre de titres composant le capital de l’émetteur au début du programme                4 387 757Capital auto détenu de manière directe et indirecte au début du programme (en titres + %) :…Exercice d’options attribuées aux salariés, de titres de créances donnant accès au capital A la date d’établissement de la présente déclaration Pièce jointe2020 12 Rachat Actions

London, January 08, 2021 – Avenir LNG Limited (NOTC: AVENIR) announces the launching of its third 7,500 cbm dual-purpose, liquefied natural gas supply and bunkering vessel, Avenir Aspiration from Nantong CIMC Sinopacific Offshore & Engineering Co.Avenir Aspiration will now undergo final outfitting before commissioning, and gas and sea trials in time for a mid-2021 delivery. Nantong CIMC Sinopacific Offshore & Engineering Co. is building an additional 7,500 cbm and two 20,000 cbm-capacity LNG carriers all for delivery later this year, bringing Avenir’s total fleet to 6 specialised LNG vessels.Peter Mackey, CEO Avenir LNG Limited, commented: “We are delighted with the successful launching of our 3rd vessel. Congratulations to our Partners at CIMC SOE for reaching this important milestone. Our fleet is the backbone of Avenir’s asset-enabled...

COMMUNIQUE FINANCIERLesquin, le 8 Janvier 20211. Generix Group – Bilan semestriel du contrat de liquidité GENERIX contracté avec NATIXIS ODDO BHFAu titre du contrat de liquidité confié à NATIXIS ODDO BHF portant sur les actions de la société GENERIX, à la date du 31 Décembre 2020, les moyens suivants figuraient au compte de liquidité : 19 279 titres GENERIX 115 829,91€     Lors du dernier bilan semestriel, à la date du 30 Juin 2020, les moyens suivants figuraient au compte de liquidité :  21 091 titres GENERIX  97 376,30€      Sur la période du 01/07/2020 au 31/12/2020 ont été exécutés :542 Transactions à l’achat498 Transactions à la vente   Sur cette même période, les volumes échangés ont représenté :64 825 titres et 457 738,50€ à l’achat66 637 titres et 476 191,20€ à la vente      Contacts Communication Financière :Generix Group...